Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proline plus gagliflozin in elderly Chinese patients with type 2 diabetes mellitus and hypertension
ChiCTR2500106345Phase 4Not yet recruiting
- Sponsor
- Luoyang Oriental Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of janagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN), sponsored by Luoyang Oriental Hospital. Primary endpoint: Achievement of clinical control of glycated hemoglobin at 8 weeks of treatment. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
janagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2500106345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106345.